Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5693-5699

  Curigliano, Giuseppe ^a   Viale, Giuseppe ^a   Bagnardi, Vincenzo ^a   Fumagalli, Luca ^a   Locatelli, Marzia ^a   Rotmensz, Nicole ^a   Ghisini, Raffaella ^a   Colleoni, Marco ^a   Munzone, Elisabetta ^a   Veronesi, Paolo ^a   Zurrida, Stefano ^a   Nolè, Franco ^a   Goldhirsch, Aron ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HAZARD RATIO; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TUMOR VOLUME; BREAST TUMOR; CHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 73349142700     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.0962     Document Type: Article

References (26)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986
3. Hudziak RM, Schlessinger J, Ulrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
4. Di Fiore PP, Pierce JH, Krasu MH, et al: ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987
5. Guy CT, Webster MA, Schaller M, et al: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578-10582, 1992
6. Chazin VR, Kaleko M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859-1866, 1992
7. Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that have progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
9. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable: HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
11. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (suppl 1; abstr 1)
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
13. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
14. Rosen PP, Oberman H: Tumors of the Mammary Gland. Washington, DC, Armed Forces Institute of Pathology, 1993
15. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer - Experience from a large study with long-term follow-up. Histopathology 41: 151-152, 2002; discussion 152-153
16. Black D, Younger J, Martei Y, et al: Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 100:S92, 2006 (suppl 1; abstr 2037)
17. Rakkhit R, Broglio K, Peintinger F, et al: Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Cancer Therapy and Research Center at University of Texas-American Association for Cancer Research Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008. Cancer Res 69:S96, 2009 (suppl; abstr 701)
18. Tovey SM, Marla S, Brown S, Burton, et al: Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours: Implications for trastuzumab therapy? Cancer Therapy and Research Center at University of Texas-American Association for Cancer Research Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008; Cancer Res 69:S96, 2009 (suppl; abstr 702)
19. Howell A, Cuzick J, Baum M: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
20. Dowsett M, Houghton J, Iden C, et al: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to estrogen receptor, progesterone receptor, EGF receptor, and HER2 status. Ann Oncol 17:818-826, 2006
21. De Placido S, De Laurentiis M, Carlomagno C, et al: Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039-1046, 2003
22. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
23. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005
24. Ellis MJ, Tao Y, Young O, et al: Estrogen-independent proliferation is present in estrogenreceptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019-3025, 2006
25. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23-28, 2008
26. Fallowfield L: Acceptance of adjuvant therapy and quality of life issues. Breast 14:612-616, 2005